



**ASX & MEDIA RELEASE
12 APRIL, 2011**

NOVOGEN REGAINS COMPLIANCE WITH NASDAQ LISTING RULE

Novogen Limited (ASX: NRT NASDAQ:NVGN) - In addition to its listing on the Australian Stock Exchange, the Company has an American Depositary Receipt (ADR) program with the ADRs listed on the Nasdaq Capital Market. Each ADR represents 5 of the Company's listed shares.

The Company announced to the market on 23 July, 2010 that it had received a notice from Nasdaq advising that it was no longer in compliance with the Nasdaq listing requirements and allowing 180 days in which to correct the non-compliance. The Company was granted an additional 180 calendar days, or until 18 July, 2011, to regain compliance in accordance with Nasdaq Rule 5810(c)(3)(A).

On 6 April, 2011 the Company received a further notice from Nasdaq confirming that for the ten consecutive business days, from 23 March, 2011 to 5 April, 2011, the closing bid price of the Company's common stock had been at US\$1.00 per ADR or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

This notification from the Nasdaq Stock Market has no bearing on the ASX listing.

About Novogen Limited

Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen has a consumer healthcare business, conducts research and development on oncology therapeutics through its 65 per cent owned subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its 80.7 per cent owned subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR LISTINGS	:	NOVOGEN LIMITED ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER INFORMATION	:	MR BILL RUECKERT, CHAIRMAN, NOVOGEN LIMITED TEL (02) 9878 0088 http://www.novogen.com
ISSUED BY	:	WESTBROOK COMMUNICATIONS CONTACT: IAN WESTBROOK TEL (02) 9231 0922, 0407 958 137